In in vivo models of melanoma, ovarian and colon cancer treatment with mFRβ-targeting CAR T cells led to the specific depletion of the FRβ+ TAM population compared to control hCD19 CAR or untransduced T cells 6 days after T cell infusion. This evidence concerns the gene CXADR and colonic neoplasm.